RNASEL and prostate cancer: The results presented here identify XMRV infection in prostate tissue from approximately 40% of patients with prostate cancer who are homozygous for the R462Q variant (QQ) of RNase L, as judged by both hybridization to the Virochip microarray and by RT-PCR with XMRV-specific primers.